Immunovant (IMVT) Stock Price, Quote, News & History | Benzinga

SPY763.54−1.24%QQQ706.47−2.58%BTC/USD81,053.76−3.53%DIA527.22−0.09%GLD369.74−2.43%TLT81.55+1.63%

Immunovant Inc (IMVT) Stock Price, Quote, News & History

IMVTNASDAQ

Trade with Public

Trade with Public

$28.68

0.301.06%

Last update: Oct 22, 12:59 PM

$28.26

-0.12-0.42%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$28.09

Close

-

Volume / Avg.

311.03K / 1.31M

Day Range

$27.98 - $29.11

52 Wk Range

17.68 - 45.42

Market Cap

$5.92B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

18.74%

Days to Cover

9.64

Recent Immunovant, Inc. News

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.

Avi Kapoor

Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.

Avi Kapoor

Immunovant Ends Autoimmune Skin Disorder Program

Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.

Vandana Singh

CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sandler increased price target for TRV, and more.

Avi Kapoor

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-414.30M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

612.93M

Free Cash Flow (TTM)

-414.31M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

198.62M

Analyst Trends and Forecast

3

May

1

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.96B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.97

Earnings Yield % (TTM)

-9.90%

Earnings Yield % (FWD)

-10.04%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.56

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$797.80M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-